1. Home
  2. MGIH vs IBO Comparison

MGIH vs IBO Comparison

Compare MGIH & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGIH
  • IBO
  • Stock Information
  • Founded
  • MGIH 1978
  • IBO 2018
  • Country
  • MGIH Hong Kong
  • IBO United States
  • Employees
  • MGIH N/A
  • IBO N/A
  • Industry
  • MGIH Publishing
  • IBO
  • Sector
  • MGIH Consumer Discretionary
  • IBO
  • Exchange
  • MGIH Nasdaq
  • IBO NYSE
  • Market Cap
  • MGIH 18.7M
  • IBO 16.5M
  • IPO Year
  • MGIH 2023
  • IBO 2024
  • Fundamental
  • Price
  • MGIH $1.63
  • IBO $2.99
  • Analyst Decision
  • MGIH
  • IBO
  • Analyst Count
  • MGIH 0
  • IBO 0
  • Target Price
  • MGIH N/A
  • IBO N/A
  • AVG Volume (30 Days)
  • MGIH 15.1K
  • IBO 68.2K
  • Earning Date
  • MGIH 11-22-2024
  • IBO 11-12-2024
  • Dividend Yield
  • MGIH N/A
  • IBO N/A
  • EPS Growth
  • MGIH N/A
  • IBO N/A
  • EPS
  • MGIH N/A
  • IBO 0.01
  • Revenue
  • MGIH $38,530,773.00
  • IBO N/A
  • Revenue This Year
  • MGIH N/A
  • IBO N/A
  • Revenue Next Year
  • MGIH N/A
  • IBO N/A
  • P/E Ratio
  • MGIH N/A
  • IBO $247.47
  • Revenue Growth
  • MGIH N/A
  • IBO N/A
  • 52 Week Low
  • MGIH $0.89
  • IBO $1.22
  • 52 Week High
  • MGIH $9.57
  • IBO $3.20
  • Technical
  • Relative Strength Index (RSI)
  • MGIH 51.33
  • IBO N/A
  • Support Level
  • MGIH $1.52
  • IBO N/A
  • Resistance Level
  • MGIH $1.69
  • IBO N/A
  • Average True Range (ATR)
  • MGIH 0.10
  • IBO 0.00
  • MACD
  • MGIH 0.01
  • IBO 0.00
  • Stochastic Oscillator
  • MGIH 80.00
  • IBO 0.00

About MGIH Millennium Group International Holdings Limited

Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products and corrugated products.

About IBO IMPACT BIOMEDICAL INC

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Share on Social Networks: